Diabetes

  • Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.

    Load more

    Type 2 diabetes is a major risk factor for the development of cardiovascular disease and cerebrovascular incidents. A substantial body of evidence has demonstrated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular diseases such as retinopathy and nephropathy.

    In the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the overall mortality significantly increased by strict control of blood glucose (target HbA1c <6%) compared with a less stringent control (target HbA1c of approximately 7%). Strict glucose control resulted in a significantly higher likelihood of developing severe hypoglycaemia, while severe hypoglycaemia was itself associated with death due to CVD.

    Load Less

Videos

Webinars

Type 2 Diabetes (T2D)

Type 2 Diabetes Mellitus

CV Outcomes in Diabetes

Risk reduction with antihyperglycemics

Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).

The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.

CV specialists are well-positioned to play a key role in managing patients with T2D including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycemic agents into routine practice.


The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

novo nordisk

Section Editor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

  • Effects of liraglutide on cardiovascular outcomes in patients

    The effects of liraglutide on cardiovascular events and mortality in LEADER participants were investigated. The study concluded that liraglutide is suitable for patients with T2D with or without HF.

    Marso SP, Baeres FMM, Bain SC, et al. J Am Coll Cardiol 2020;75:1128–41.
  • Dapagliflozin in Patients with HF and HFrEF

    This method paper details the DAPA-HF trial. The ground-breaking DAPA-HF trial showed that among patients with HF and a HFrEF, those who received the SGLT2i dapagliflozin had a lower risk of worsening HF or death from CV causes, regardless of the...

    McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med 2019;381:1995–2008.
  • Cardio-diabetology: The new ‘sweetheart’ in cardiovascular prevention

    This special issue accompanies the cardiovascular specialists from the pre-diabetic state to the holistic approach of the management of diabetes and the metabolic syndrome up to the management of those experiencing a cardiovascular event.

    Aboyans V, Cosentino F. Eur J Prev Cardiol 2019;26(2 Suppl):5–6.
  • GLP-1RA for prevention of CR outcomes in T2D

    This meta-analysis of GLP-1RA CVOTs sheds new light on the cardiorenal efficacy of GLP-1RAs in patients with T2D.

    Giugliano D, Maiorino MI, Bellastella G, et al. Diabetes Obes Metab 2019;21:2576–80.

Pages

Clinical publications

Pages

Ongoing trials

Review articles

Pages

Guidelines

Pages

Treating calcium with Shockwave IVL – The impact of DISRUPT CADIII on clinical practice

Treating calcium with Shockwave IVL – The impact of DISRUPT CADIII on clinical practice

Wednesday 16th December 2020
@ 15:00 (CET)

Reserve Your Seat for this event.

 

This is a live case of complex calcified coronary disease to demonstrate how easily and safely Intravascular Lithotripsy (IVL) can be used to prepare the calcified lesion prior to stenting.

Get insights on Intravascular Lithotripsy (IVL) applications and how it fits into the calcium treatment algorithm

Hear discussion on the DISRUPT CAD III results and new findings from the OCT sub-study analysis and how it might change current practice when dealing with calcified plaques.

If you would like to conduct some further research, please follow the link here to review the TCT Connect 2020: The Disrupt CAD III Trial.

  • See how Complex PCI operators plan and perform a complex calcified coronary case using Intravascular Lithotripsy (IVL)
  • Understanding the mechanism of action of IVL based on the latest OCT evidence
  • Review the latest results from DISRUPT CADIII clinical trial

*Draft agenda, subject to change

Introduction & Objectives of meeting15:00 - 15:0500:05Prof Holger Nef
Live Case15:05 - 15:4000:35Dr Kambis Mashayekhi & Dr Miroslaw Ferenc
CADIII data overview15:40 - 15:5000:10Prof Holger Nef
Post case discussion, Q&A and closing remarks 15:50 - 16:0000:10All faculty

 

Case Moderator

Prof Holger Nef, MD
Senior Physician, Dpeartment of Cardiology, Kerckhoff and associate Director, Department of Medical Click I, University of Giessen, DE

 

Case Operators

Dr Kambis Mashayekhi
Deputy Medical Director, General and Interventional Cardiology Department of Cardiology and Angiology II University Heartcenter Freiburg – Bad Krozingen, DE

 

Dr Miroslaw Ferenc
Head of Intervetional Cardiology Department, University Heart Centre Freiburg – Bad Krozingen, DE

 

This webinar is aimed at Interventional Cardiologist.

Please follow the link to our webpage and to CADIII microsite: https://cadiii.shockwavemedical.com/

 
This webinar is supported by:

Pages

Subscribe to RSS - Diabetes